

# Specified Drug-Use Survey of Leuprorelin Acetate Injection Kit 11.25 mg "All-Case Investigation: Spinal and Bulbar Muscular Atrophy (SBMA)"

NCT03555578

---

**Status** RECRUITING  
**Sponsor** Takeda  
**Enrollment** 1,890 participants

## Key Eligibility Criteria

---

### Inclusion (1)

- All SBMA patients who have been confirmed as receiving the drug

### Exclusion (1)

- None

## Locations (1 total)

---

Takeda Selected Site, Tokyo, Japan